Cargando…
Histone deacetylase inhibitor givinostat alleviates liver fibrosis by regulating hepatic stellate cell activation
Hepatic fibrosis, a common pathological manifestation of chronic liver injury, is generally considered to be the end result of an increase in extracellular matrix produced by activated hepatic stellate cells (HSCs). The aim of the present study was to target the mechanisms underlying HSC activation...
Autores principales: | Huang, He-Ming, Zhou, Xiao-Ru, Liu, Yan-Jun, Fan, Shi-Jie, Liao, Li-Ping, Huang, Jing, Shi, Cui-Cui, Yu, Liang, Pen, Jin-Jin, Luo, Cheng, Zhang, Yuan-Yuan, Li, Guang-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7974418/ https://www.ncbi.nlm.nih.gov/pubmed/33649839 http://dx.doi.org/10.3892/mmr.2021.11944 |
Ejemplares similares
-
Histone deacetylase inhibitor givinostat has ameliorative effect in the colitis model
por: Dibekoğlu, Cengiz, et al.
Publicado: (2022) -
An immediate transcriptional signature associated with response to the histone deacetylase inhibitor Givinostat in T acute lymphoblastic leukemia xenografts
por: Pinazza, M, et al.
Publicado: (2016) -
Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia
por: Li, Ying, et al.
Publicado: (2016) -
Targeting glutamine metabolism in hepatic stellate cells alleviates liver fibrosis
por: Yin, Xiaochun, et al.
Publicado: (2022) -
Inhibition of 5-Lipoxygenase in Hepatic Stellate Cells Alleviates Liver Fibrosis
por: Pu, Shiyun, et al.
Publicado: (2021)